Bibliography from FDA Background Document September 23, 2004 VRBPAC Meeting:

 

1Meeting Summary: AIDS Vaccine Trials, Considerations for Phase III Trial Design and Endpoints.National Institutes of Health, NIAID, November 16, 2001.Retrieved from the World Wide Web on August 3, 2004 at http://www.niaid.nih.gov/vrc.

 

2NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed.NIAID News, February 25, 2002.Retrieved from the World Wide Web on August 9, 2004 at http://www2.niaid.nih.gov/newsroom/releases/phase3hiv.htm.

 

3Burton DR, Desrosiers RC, Doms RW, et al.Public health.A sound rationale needed for phase III HIV-1 vaccine trials.Science 2004;303:316.

 

4McNeil JG, Johnston MI, Birx DL, Tramont EC.Policy rebuttal.HIV vaccine trial justified.Science 2004;303:961.

 

5Trinvuthipong, D.Thailandís prime-boost HIV vaccine trial phase III.Science 2004;303:954-5.

 

6Letters to the Editor.Science 2004;305:177-180.

 

7Tangcharoensathien V, Wiput P, Pitayarangsarit S, et al.The potential demand for an AIDS vaccine in Thailand.Health Policy 2001;57:111-139.

 

8Nitayaphan S, Pitisuttithum P, Karnasuta C, et al.Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.Journal of Infectious Diseases 2004;190:702-6.

 

9Tovanabutra S, et al.Characterization of full-length HIV-1 genomes from non-B subtype infections in U.S. military personnel.AIDS Vaccine 2003, New York, NY; Abstract number 463.

 

10McCarthy M.AIDS vaccine fails in Thai trial.Lancet. 2003 Nov 22;362(9397):1728.

 

11de Bruyn G, Rossini AJ, Chiu Y, et al.Safety profile of recombinant canarypox HIV vaccines.Vaccine 2004;22:704-13.

 

12Klausner RD, Fauci AS, Corey L, et al.The need for a global HIV vaccine enterprise.Science 2003;300:2036-39.